Vanda Pharmaceuticals Inc.

VNDA Healthcare Biotechnology

Vanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024. In the quarter to June 2026, revenue fell 3.92%, EPS fell 126.1%, free cash flow fell 101.0% and total debt rose 2.98%, each against the same quarter a year earlier.

4.03 0.21 −4.95%
Market cap
$256.4M
P/E
0.0×
Fwd P/E
−2.6×
Dividend yield
—
F-score
2/9
Altman Z
0.72
Beneish M
−3.88
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 86.26 61.83 26.15 30.56 7.56 52.26 0.00 0.00
Piotroski F-Score
2 3 5 4 6 6 4 7 5 6
Altman Z-Score
0.72 1.77 1.93 3.23 7.00 6.24 7.90 14.34 4.16 4.07
P/S ratio
2.41 1.40 1.35 1.65 3.24 2.88 3.84 6.89 4.23 4.64
P/FCF ratio
0.00 0.00 0.00 66.45 22.54 28.63 43.76 288.01 0.00 0.00
Altman Z″-Score (non-manufacturers)
0.13 6.91 8.09 8.85 10.00 9.29 8.75 7.10 (1.25) (0.35)
Beneish M-Score
(3.88) (2.27) (2.09) (2.72) (2.71) (2.79) (1.02) (1.83) (2.95) (2.57)
P/Operating CF
(17.67) (153.29) (69.50) 44.49 32.76 37.05 89.06 87.14 201.35 (572.96)
P/B ratio
1.59 0.52 0.48 0.79 1.73 1.58 2.12 4.83 5.31 5.16
Price to Tangible BV
2.47 0.66 0.61 0.82 1.80 1.66 2.25 5.30 6.63 6.55
EV/Sales
1.20 (0.47) (0.63) (0.15) 1.67 1.45 2.52 5.55 3.36 3.67
EV/EBITDA
0.00 2.46 6.59 0.00 9.62 11.85 25.32 47.73 0.00 0.00
EV/Operating CF
(2.38) 5.90 (9.49) (1.22) 6.99 6.93 12.46 35.77 (279.60) (66.21)
EV/FCF
(2.35) 2.04 1.07 (6.20) 11.61 14.37 28.72 232.28 (152.03) (29.44)
Quick Ratio
2.19 4.22 4.82 5.47 6.25 6.03 5.69 5.40 2.29 3.21
Current Ratio
2.39 4.39 4.94 5.68 6.43 6.21 5.95 5.64 2.41 3.46
Net Debt/EBITDA
1.84 9.81 21.08 (75.10) (9.06) (11.76) (13.26) (11.45) 10.00 21.09
Debt/Assets
0.83% 0.48% 0.00% 1.39% 1.69% 2.16% 2.57% 0.00% 0.00% 0.00%
Debt/Equity
0.01 0.01 0.00 0.02 0.02 0.03 0.03 0.00 0.00 0.00
Asset Turnover
0.38 0.30 0.30 0.41 0.48 0.49 0.56 0.72 0.79 0.69
Operating CF/Net income
0.50 0.83 5.10 5.10 1.94 2.22 0.40 1.19 0.13 0.45
Capex/Depreciation
(0.10) (1.68) 22.63 2.95 (0.12) (0.59) 4.92 (34.51) (0.65) (0.12)
ROE
(50.93%) (3.49%) 0.47% 1.22% 6.92% 5.40% 33.67% 12.39% (11.85%) (13.63%)
ROA
(38.51%) (2.90%) 0.39% 1.02% 5.88% 4.59% 28.33% 9.38% (7.49%) (8.51%)
ROIC
(140.15%) (15.21%) (5.57%) 5.72% 32.07% 17.55% 12.81% 75.22% 0.00% 0.00%
Return on Tangible Assets
(107.89%) (5.54%) 0.72% 1.46% 8.15% 6.72% 38.71% 10.06% (14.85%) (13.98%)
Average Days of Receivables
92.18 86.49 64.71 48.08 44.11 44.18 42.36 54.40 38.92 50.66
Research and Development Expense of Revenue
50.56% 37.45% 39.88% 33.72% 28.05% 22.39% 21.41% 22.57% 23.35% 19.97%
Selling, General and Administrative Expense of Revenue
110.11% 73.66% 58.60% 53.65% 46.17% 56.62% 57.11% 54.76% 75.02% 68.34%
Intangible Assets out of Total Assets
0.24 0.17 0.19 0.03 0.03 0.04 0.05 0.07 0.13 0.13
Share Based Compensation of Revenue
4.38% 6.25% 7.29% 6.40% 5.72% 5.38% 5.92% 6.04% 6.34% 5.85%
Graham Net Nets
0.36 1.15 1.27 0.98 0.45 0.46 0.32 0.18 0.14 0.14
Graham Number
0.00 0.00 3.35 5.02 11.08 8.98 19.43 7.80 0.00 0.00
Earnings Yield
(42.29%) (6.68%) 1.16% 1.62% 3.82% 3.27% 13.22% 1.91% (2.18%) (2.70%)
Free Cash Flow Yield
(21.25%) (16.33%) (43.66%) 1.50% 4.44% 3.49% 2.29% 0.35% (0.52%) (2.69%)
Revenue per Share
3.67 3.42 3.36 4.51 4.84 4.56 4.28 3.79 3.69 3.36
Operating CF per Share
(1.86) (0.27) 0.22 0.57 1.16 0.95 0.86 0.59 (0.04) (0.19)
Capex per Share
(0.02) (0.08) (1.76) (0.01) (0.01) (0.03) (0.02) (0.50) (0.04) (0.03)
Free Cash Flow per Share
(1.87) (0.35) (1.54) 0.55 1.15 0.92 0.85 0.09 (0.08) (0.22)
Cash per Share
4.48 6.44 6.77 8.27 7.79 6.76 5.87 5.06 3.21 3.25
Shareholders Equity per Share
5.55 9.26 9.50 9.34 9.09 8.33 7.73 5.41 2.94 3.02
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
5.55 9.26 9.50 9.34 9.09 8.33 7.73 5.41 2.94 3.02
Free Cash Flow
(110.44) (20.48) (88.25) 31.31 63.66 49.98 44.93 4.62 (3.65) (9.51)
Working Capital
202.10 338.91 345.25 427.86 403.88 343.21 294.63 246.12 99.49 123.86
Capital Expenditures
(1.00) (4.72) (101.05) (0.68) (0.55) (1.79) (1.02) (25.37) (1.66) (1.41)
Net Current Asset Value
185.50 321.23 329.42 412.24 389.44 328.96 281.33 242.42 95.82 95.13
EV/EBIT
0.00 2.29 8.70 0.00 10.64 13.18 25.09 49.34 0.00 0.00
Capex to Sales
0.00 0.02 0.52 0.00 0.00 0.01 0.00 0.13 0.01 0.01
Price to Operating Income
0.00 0.00 0.00 66.20 20.67 26.26 38.23 61.18 0.00 0.00
Other line items
Depreciation/Fixed assets
4.39 1.32 (2.19) (0.09) 1.44 0.74 (0.05) 0.17 0.48 2.37
Cash ROIC
(18.56%) (2.23%) (9.46%) 3.12% 6.72% 6.00% 6.11% 0.87% (1.33%) (3.49%)
Accounts Receivable Turnover
4.25 4.89 5.69 7.71 8.60 8.80 8.24 8.33 8.72 7.98
Accounts Payable Turnover
0.24 0.29 0.35 0.61 0.78 0.79 1.00 0.98 0.98 1.55
Inventory Turnover
7.29 7.34 11.60 21.89 22.24 19.31 22.95 22.36 22.05 23.84
Average Days of Payables
1,911.10 1,260.95 948.76 684.71 490.46 492.24 411.24 384.15 415.86 239.22
Days of Inventory on Hand
51.82 55.68 33.48 17.95 14.60 20.00 16.99 17.69 17.18 11.51
Average Receivables
50.84 40.63 33.83 32.99 31.25 28.20 27.57 23.19 18.93 18.30
Average Payables
53.69 38.77 42.01 39.99 32.97 29.55 24.59 20.96 18.27 15.98
Average Inventory
1.79 1.54 1.28 1.11 1.15 1.21 1.07 0.92 0.81 1.04
Average Assets
572.58 652.32 641.34 614.02 563.62 508.60 407.94 268.78 207.90 211.71
Average Common Equity
432.87 541.73 536.05 516.06 479.10 432.11 343.18 203.40 131.36 132.18

Fold the line items

Columns are period end dates